UM’s Kevin Van der Jeught is working to improve intratumoral mRNA vaccination in hope of providing new therapies to people with advanced colorectal cancer. team is at the forefront of developing orthotopic endoscopy-guided intratumoral mRNA injection into CRC tumors.
However, they are now focusing on a new strategy: delivering mRNA to dendritic cells, a specific immune cell that is at the basis of driving anti-tumor immune responses. “The main goal of this proposal is to knock down immune checkpoint targets and see how targeting these could improve mRNA vaccination,” says Van der Jeught. “Our goal is to ensure that our work has a real chance to make it to the clinic and help patients.”
View Related Expert Profiles: Go to Source
